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Background: Recently, the American Joint Committee on Cancer (AJCC) released its
8th edition changes to the staging system for hepatocellular cancer (HCC). We sought
to validate the 8th edition staging system and compare the performance to the 7th
edition using a population-based data set.
Methods: Using the Surveillance, Epidemiology and End Results (SEER) database
(1998-2013), patients undergoing resection or transplant for non-metastatic HCC
were identified. Overall survival was estimated using the Kaplan-Meier method and
compared using log-rank tests. Concordance indices (c-indices) were calculated from
Cox proportional hazards models to evaluate discriminatory power.
Results: The study included 8918 patients resected (63%) or transplanted (37%) for
HCC. Nodal staging was performed in 19%, of whom 5% had positive nodes. The c-
index for the AJCC 8th edition staging system was 0.60, similar to that for the 7th
edition (0.59). Survival was better for solitary tumors >2 cmwith vascular invasion than
for multifocal tumors <5 cm (median not reached vs 57 months, P < 0.0001), although
the staging system groups these tumors together as T2. For multifocal tumors ≤5 cm,
those with vascular invasion had worse survival than those without (median 42 vs
50 months, P < 0.001), although the staging system draws no such distinction.
Conclusion:TheAJCC8th edition staging system forHCCperforms similarly to the 7th
edition. Future revisions should consider substratification of early HCC, specifically by
distinguishing solitary tumors >2 cm frommultifocal tumors ≤5 cm, and by considering
the prognostic impact of vascular invasion in multifocal tumors ≤5 cm. Future studies
should aim to validate these findings.
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1 | INTRODUCTION
Hepatocellular carcinoma (HCC) accounts for 90% of primary liver
cancer and is the 6th most common malignancy in the United States
(US).1,2 Its annual US incidence is expected to double by 2030.1,3 In
2016, there were 39 000 new cases of HCC and 27 000 deaths. Even
after potentially curative surgical extirpation, the 5-year survival rates
are only 30% and 60% for resection and transplant, respectively.4
Novel therapeutic strategies ought to be tested in clinical trials to
further improve outcomes in this cohort of patients. A well-defined
staging system which accurately discriminates prognosis is needed in
order to accurately stratify patients for such studies.
Recently, the American Joint Committee on Cancer (AJCC)
released the new 8th edition staging system (Table 1), which
incorporates several changes to the T classifications from the previous
7th edition staging system (Table 2).5,6 Previously, early HCC were
categorized as T1 (solitary tumor, any size, no vascular invasion) or T2
(solitary tumor, any size, with vascular invasion; or multifocal tumors,
none >5 cm, with or without vascular invasion). The new staging
system defines T1a tumors as solitary tumors ≤2 cm with or without
vascular invasion. Solitary tumors >2 cm without vascular invasion
(previously T2), are now separately classified as T1b. Larger solitary
tumors >2 cmwith vascular invasion as well as multifocal tumors, none
>5 cm, continue to be classified as T2. Larger multifocal tumors ≥5 cm
remain classified as T3 disease. Finally, major vascular invasion
(previously T3b) now qualifies as T4 disease.
Although multiple changes have been made in the AJCC 8th
edition staging system, their impact on the prognostic value of the
staging system has yet to be evaluated. Hence, we sought to validate
the 8th edition staging system for HCC using a population-based data
set. In particular, we sought to whether the staging of early HCC is
appropriate, specifically whether further subdivision of T2 tumors
should be considered.
2 | METHODS
2.1 | Data source and study cohort
Prospectively collected data from the Surveillance, Epidemiology, and
End Results (SEER) database maintained by the National Cancer
Institute were used for analysis in this study. The SEER database has
grown to include 21 cancer registries, representing 28% of the United
States population. As compared to the general US population, the
SEER population is slightly more urban and has a slightly higher
percentage of foreign-born individuals. Available data included patient
demographics (eg, age, gender, race), tumor data (histology, grade,
stage), and treatment data (surgery, radiation). Some data elements (eg,
AJCC staging, details of surgical therapy, tumor size, lymph node
involvement) are consistently available only in more recent time
periods.
Using SEER data from 1998 to 2013, we identified patients
aged 18-99 years with surgically extirpated (via resection or
transplant), histologically confirmed non-metastatic hepatocellular
carcinoma (HCC). Only patients undergoing surgical extirpation (ie,
resection and liver transplant) were included because staging
variables are reliably ascertainable from pathological specimens.
This enables a valid appraisal of the new staging system for HCC.
International Classification of Disease 3rd edition (ICD-O3) were
used to identify HCC using site codes C220. Histology codes were
used to specifically identify patients with HCC (8170-8175). Other
variants of HCC and non-specific histologies (eg, “neoplasm” or
“carcinoma, NOS,”) were excluded from the analysis. Likewise,
cases with vague histology codes of “neoplasm” (8000-8003),
“carcinoma, NOS” (8010-8013), and “carcinoma undifferentiated,
NOS” (8120-8122) were excluded (NOS, not otherwise specified).
The AJCC 7th and 8th edition staging systems were derived using
data on tumor size, lymph node involvement, number of tumors and
vascular invasion, all of which are provided by the SEER database. In
this study, c-indices were not calculated for patients with N1
classification due to small numbers. Cases with missing data for
these variables were excluded.
2.2 | Statistical analysis
Categorical variables were compared using the chi-squared test. Non-
normally distributed data were analyzed using the Mann-
Whitney U test. Overall survival was estimated using Kaplan-Meier
survival curves and compared using the log-rank test. Overall survival
was chosen because this is the survival metric used by the AJCC and
avoids potential bias from attribution of cause of death. A concordance
index (c-index) was calculated to evaluate the discriminatory power of
each staging system.7 A value of 0.5 indicates chance alone is as
predictive as the staging system,whereas a level of 1.0 signifies perfect
concordance. A Cox proportional hazards model was used with T
classification coded as indicator variables to obtain hazard ratios (HR),
and the concordance index was calculated from this Cox model.8 Cox
proportional hazards modeling was also used to assess differences in
survival after resection vs transplant. A separate model adjusting for
potential confounding variables including sex, age, and race was also
assessed. Stratified analyses were also carried out to examine impact
of the staging systems in patients undergoing resection and
transplantation separately, and c-indices for these subgroups were
separately evaluated. A P-value of <0.05 was considered to be
statistically significant. Data analysis were performed using R
Foundation Statistical software (R 3.2.1) with TableOne, ggplot2,
Hmisc, and survival packages (R Foundation for Statistical Computing,
Vienna, Austria).
3 | RESULTS
3.1 | Patient demographics and time trends
This study cohort included 8918 patients who underwent surgery for
HCC between 1998 and 2013. Clinicopathologic data for the entire
cohort are presented in Supplemental Table S1. In this cohort, 5590
(63%) of patients had a surgical resection, and 3328 (37%) patients
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received a liver transplant. Only 19% (1540/8918) of patients in the
entire cohort had lymph nodes examined. Among patients undergoing
liver resection, the rate of lymph node examination was 14% (772/
5594), significantly lower than among those receiving a liver transplant
(26%, 870/3328, P < 0.001). Of those with at least one 1 lymph node
examined, the median number examined was 1 (interquartile range,
IQR 1-2), and the incidence of positive lymph nodes was 5%. In
patients undergoing surgical resection, the incidence of positive lymph
nodes was 9% (68/702), higher than in patients receiving liver
transplant for HCC (1%, 12/852).
TABLE 2 AJCC 7th Edition Staging System for Hepatocellular carcinoma
Primary tumor (T) Regional lymph nodes (N) Distant metastases (M)
T1 Solitary tumor without vascular invasion Nx Regional lymph nodes
cannot be assessed
M0 No distant metástasis
T2 Solitary tumor with vascular invasion, or
multifocal tumors, none >5 cm
N0 No regional lymph
node metastasis
M1 Distant metastasis
T3a Multifocal tumors at least one of which is >5 cm N1 Regional lymph node metastasis
T3b Single tumor or multifocal tumors of any size involving
a major branch of the portal vein or hepatic vein
T4 Tumor with direct invasion of adjacent organs other
than the gallbladder or with perforation of the
visceral peritoneum
Stage
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage IIIA T3a N0 M0
Stage IIIB T3b N0 M0
Stage IIIC T4 N0 M0
Stage IVA Any T N1 M0
Stage IVB Any T Any N M1
TABLE 1 AJCC 8th Edition Staging System for Hepatocellular carcinoma
Primary tumor (T) Regional lymph nodes (N) Distant metastases (M)
T1a Solitary tumor <2 cm with/without vascular invasion Nx Regional lymph nodes
cannot be assessed
M0 No distant metastasis
T1b Solitary tumor >2 cm without
vascular invasion
N0 No regional lymph node
metastasis
M1 Distant metastasis
T2 Solitary tumor >2 cm with vascular invasion
or multifocal tumors, none >5 cm
N1 Regional lymph node
metastasis
T3 Multifocal tumors at least one of which is >5 cm
T4 Single tumor or multifocal tumors of any size
involving a major branch of the portal
vein or hepatic vein or tumor(s) with
direct invasion of adjacent organs
other than the gallbladder or with
perforation of visceral peritoneum
Stage
Stage IA T1a N0 M0
Stage IB T1b N0 M0
Stage II T2 N0 M0
Stage IIIA T3 N0 M0
Stage IIIB T4 N0 M0
Stage IVA Any T N1 M0
Stage IVB Any T Any N M1
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3.2 | Overall survival by T classification
As expected in the new AJCC 8th edition staging system, T1
tumors had the best prognosis (median survival 48 months, CI95%:
47-50 months), followed by T2 (45 months, CI95%: 44-46 months),
T3 (33 months, CI95%: 32-35 months), and T4 tumors (28 months,
CI95%: 27-30 months P < 0.001). However, the difference in
survival between T1a and T1b tumors (50, CI95%: 49-51 vs 47,
CI95%: 46-48 months, P < 0.001) was larger than that for T1b and
T2 tumors (47 vs 45 months, P = 0.031) (Figure 1). Cox regression
for N0 and Nx tumors demonstrated significant differences in
survival between the new AJCC 8th edition T-classifications
(Table 3). The corresponding c-index for the 8th edition T
classification was 0.60 (CI95%: 0.59-0.61), similar to that for the
7th edition (0.59, CI95%: 0.58-0.61).
We next performed analyses stratified by type of surgery (ie,
resection vs transplant). Of the 7442 patients with early HCC (ie, T1
and T2 tumors), 3128 (42%) received a liver transplant, and 4314
(58%) patients underwent liver resection. As expected, there were
significantly lower rates of liver transplant in patients with T3 and T4
tumors (14%, 200/1476; P < 0.001). Transplanted patients had
superior survival across all stages, but monotonic trends in survival
were observed in both groups. Specifically, median survival after
resection was 47 months (CI95%: 46-48) for T1, 39 months (CI95%:
38-40) for T2, 32 months (CI95%: 30-34) for T3, and 27 months
(CI95%: 24-28) for T4 tumors. Median survival after transplant was
51 months (CI95%: 49-52) for T1, 51 months (CI95%: 50-52) for T2,
43 months (CI95%: 38-46) for T3, and 43 months (CI95%: 36-45) for
T4 tumors. The corresponding c-indices were 0.62 (CI95%: 0.61-0.63)
for resection and 0.61 (CI95%: 0.60-0.62) for transplant.
3.3 | Outcomes of subgroups of T2 tumors
In the AJCC8th edition staging, T2 tumors include both solitary tumors
>2 cmwith vascular invasion and multifocal tumors ≤5 cm. There were
1381 patients with solitary tumors >2 cm and vascular invasion, and
1373 patients with multifocal tumors ≤5 cm. The 3-year (70% vs 54%),
5-year (45% vs 32%), andmedian (47, CI95%: 46-48 vs 40, CI95%: 39-42
months, all P < 0.001) survival were significantly longer for patients
having solitary tumors >2 cm with vascular invasion as compared to
thosewithmultifocal tumors ≤5 cm. Analyses stratified by nodal status
demonstrated similar survival trends favoring solitary tumors.
Among patients with T2 tumors, 1381 patients received a liver
transplant. Pathologic staging exceeded the Milan criteria in 27% (374/
1381).ThereasonforexceedingMilancriteriawasasolitary tumor>5 cmin
1% (15/1381) andmultifocal tumors>3 cm in26% (359/1381). Survival for
solitary tumors >2 cm was significantly longer than for multifocal tumors
≤5 cm in patients receiving a liver transplant, (median 52, CI95%: 51-53 vs
38, CI95%: 36-43 months, P<0.001) as well in those undergoing surgical
resection (45,CI95%:42-49vs39,CI95%:38-41months,P<0.001,Figure2).
3.4 | Impact of vascular invasion
Our analysis confirmed that for T1 tumors, vascular invasion does not
impact prognosis (median survival 50 vs 51 months, P = 0.5,
Supplemental Table S2). With regard to T2 tumors, the AJCC staging
system considers the impact of (micro)vascular invasion in solitary
tumors. However, it does not do so in multifocal tumors. As such, we
analyzed the potential impact of vascular invasion in multifocal tumors
≤5 cm. In this sub-group (n = 1106), therewere 184 (17%) patientswith
and 922 (83%) patients without vascular invasion. In patients with
multifocal tumors ≤5 cm, the median survival with vascular invasion
was significantly shorter than in the absence of vascular invasion (42,
CI95%: 38-45 vs 50, CI95%: 48-51 months; P < 0.001). When stratified
by nodal classification, patients with vascular invasion had shorter
survival than patients without vascular invasion in both the N0 and Nx
groups.
Further analyses stratified by type of surgery demonstrated that
vascular invasion remains a prognostic factor for overall survival in
both groups (Figure 3). In patients undergoing surgical resection
(n = 383), median survival with vascular invasion was significantly
shorter than in the absence of vascular invasion (33, CI95%: 27-39 vs
42, CI95%: 40-45 months; P = 0.003). For patients undergoing liver
transplant (n = 723), median survival with vascular invasion was
significantly shorter than in the absence of vascular invasion (48,
CI95%: 44-52 vs 53, CI95%: 52-54 months; P = 0.008).
3.5 | Impact of tumor size in multifocal tumors
We also evaluated the impact of tumor size on multifocal tumors using
a cut-off of 5 cm, as does the AJCC 8th edition staging system. In this
analysis, 69% (1750/2536) of patients had multifocal tumors ≤5 cm
and the remaining 31% (786/2536) had multifocal tumors >5 cm.
Survival was significantly longer among patients with multifocal
FIGURE 1 Overall survival of 8918 patients who underwent
surgery for hepatocellular carcinoma stratified by AJCC 8th edition
T classification
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tumors ≤5 cm as compared to those with multifocal tumors >5 cm (48,
CI95%: 47-49 vs 34, CI95%: 32-35 months, P < 0.001). When stratified
by surgical management, patients with tumors ≤5 cm had a signifi-
cantly longer survival than tumors >5 cm after both resection (38,
CI95%: 36-40 vs 32, CI95%: 30–34 months, P < 0.001) and liver
transplant (51, CI95%: 50-53 vs 42, CI95%: 38-46 months, P < 0.001).
4 | DISCUSSION
Using a nationally representative dataset, this study empirically
demonstrates that the new AJCC 8th edition T classifications result
in comparable discrimination to that provided by the 7th edition
staging system, even when stratified according to resection or liver
transplant. Its main improvement is in shifting the focus of
substratification to earlier HCC, which are more common and more
likely to benefit from aggressive new therapies. The system generally
performs as expected, with appropriate gradation of survival by T
classification. However, it overlooks several key prognostic elements.
For example, significant differences in survival exist between the
subgroups categorized together as T2 tumors. Furthermore, vascular
information continues to have prognostic importance in the setting of
multifocal tumors. As such, we suggest that these groups should be
distinguished in future revisions so as to continue the shift towards
substratifying earlier HCC.9–11
In this study, survival for solitary tumors >2 cm with vascular
invasionwas significantly longer than formultifocal tumors ≤5 cm. This
finding contrasts with those from amulti-center study by Shindoh et al,
which reported that survival for solitaryHCC>2 cmwithmicrovascular
invasion (median 55 months) was similar to that for multifocal HCC
≤5 cm (median 56 months, P = 0.5) in patients undergoing surgical
resection for HCC. The Shindoh report in part informed the revision of
TABLE 3 Impact of T and N classification on survival in AJCC 8th edition staging system, stratified by N classification for the entire cohort
All patients N0 Nx
HR (CI95%) P-value HR (CI95%) P-value HR (CI95%) P-value
T1a REF REF REF
T1b 1.48 (1.30-1.68) 1.21 (0.90-1.60) 1.52 (1.32-1.76)
T2 1.61 (1.41-1.83) 1.20 (0.90-1.56) 1.71 (1.48-1.98)
T3 3.20 (2.75-3.72) <0.001 2.81 (2.02-3.92) <0.001 3.25 (2.74-3.85) <0.001
T4 4.20 (3.61- 4.87) 3.43 (2.45-4.80) 4.30 (3.62-5.09)
c-index 0.60 (0.59-0.61) 0.60 (0.57-0.63) 0.60 (0.59-0.62)
FIGURE 2 Overall survival of 2754 patients who underwent
surgery for AJCC 8th edition T2 classification hepatocellular
carcinoma stratified by type of surgery (resection vs transplantation)
and number of tumors (solitary vs multifocal)
FIGURE 3 Overall survival of 1106 patients who underwent
surgery for AJCC 8th edition T2 classification hepatocellular
carcinoma with multifocal tumors ≤5 cm stratified by type of
surgery (resection vs transplantation) and presence of microvascular
invasion
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the T2 classification for the AJCC 8th edition staging system.12
However, this study may have been underpowered, as there were
relatively few patients with solitary HCC >2 cm with microvascular
invasion (n = 334) and multifocal tumors ≤5 cm (n = 80). In our study,
there were significant differences in survival between these two sub-
groups, both in the liver resection and transplant groups. Hence,
substratifying the T2 group further to differentiate solitary and
multifocal tumors is warranted.
Our analyses also demonstrate that microvascular invasion
confers an adverse prognosis in multifocal T2 tumors. However, the
current AJCC staging system does not take this into account.
Microvascular invasion has been associated with adverse prognosis
in most studies.13–16 A recent meta-analysis of pooled studies
demonstrated that microvascular invasion has prognostic value
following resection and transplantation and is closely associated
with increasing tumor size and multifocal disease.17 However, none of
these previous studies specifically evaluated the impact of vascular
invasion in multifocal tumors. In this analysis, median survival among
patients with multifocal T2 tumors was reduced from 50 to 42 months
with vascular invasion, suggesting that this prognostic factor should be
considered in further stratifying multifocal tumors ≤5 cm.
Limitations of this study include the lack of information on resection
margin status, underlying etiology and severity of cirrhosis (if any), and
viral hepatitis status. However, these are not variables that have been
historically included in the HCC staging system, even though they may
have some prognostic impact. Data on salvage therapies, such as
transarterial chemoembolization (TACE), radioembolization, ablative
therapies, and transplant as a second-line therapy, are also not reported.
This is because staging variables are ascertainable on pathological
specimens, hence allowing a valid appraisal of the staging system. Finally,
there was no centralized pathologic review of tumor specimens in this
cancer registry-based study. Despite this, previous studies have reported
good agreement between the histologic subtypes of cancer reported by
SEER and those assigned by independent reviewers.18 Notable strengths
of our study include the large population included and the robust long-
term follow-up of survival provided by SEER.
5 | CONCLUSION
In summary, the newAJCC8th edition staging systemwith its revised T
classification is valid in stratifying HCC patients undergoing surgical
extirpation performs comparably to the AJCC 7th edition staging
system. Stratified analyses by resection and liver transplant have
similar performance under the new AJCC staging system. However,
further stratification of T2 tumors may be required. Solitary tumors
with vascular invasion demonstrated a superior prognosis as compared
to multifocal tumors ≤5 cm, suggested that distinction between this
groups may be warranted, but these findings would need to be
validated in future studies. Furthermore, vascular invasion is an
important prognostic factor not only in solitary tumors, but also in
multifocal tumors, and it should be incorporated as such into the
staging system. Substratification of early HCC tumorsmay better allow
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